Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Biomarker Identification Trial for Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Carcinoma

NCT00674973 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00674973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00674973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Biomarker Identification Trial for Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Carcinoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
March 31, 2015
Enrollment
207 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer